(9S)-9-(2-Hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4, 9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4765-4770

  Sato, Nagaaki ^a   Jitsuoka, Makoto ^a   Shibata, Takunobu ^a   Hirohashi, Tomoko ^a   Nonoshita, Katsumasa ^a   Moriya, Minoru ^a   Haga, Yuji ^a   Sakuraba, Aya ^a   Ando, Makoto ^a   Ohe, Tomoyuki ^a   Iwaasa, Hisashi ^a   Gomori, Akira ^a   Ishihara, Akane ^a   Kanatani, Akio ^a   Fukami, Takehiro ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 5 FLUORO 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 6 BROMO 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 6 CHLORO 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 6 ETHOXY 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 6 ETHYL 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 6 FLUORO 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 7 CHLORO 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 7 FLUORO 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 4 METHYL 6 OXOCYCLOHEXEYL) 3 METHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 4,4 DIMETHYL 6 OXO 1 CYCLOHEXEN 1 YL) 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 3,3,6 TRIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 5 METHOXY 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 6 METHOXY 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 7 METHOXY 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 4,4 DIMETHYL 6 OXOCYCLOHEXEYL) 8 METHOXY 3,3 DIMETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (2 HYDROXY 6 OXOCYCLOHEXEYL) 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9 (4,4 DIETHYL 2 HYDROXY 6 OXOCYCLOHEXEYL) 3,3 DIETHYL 2,3,4,9 TETRAHYDRO 1H XANTHEN 1 ONE; 9' (2 HYDROXY 4 OXOSPIRO[5.5]UNDEC 3 YL) 4',9' DIHYDROSPIRO(CYCLOBUTANE 1,3' XANTHEN) 1'(2'H) ONE; 9' (6 HYDROXY 8 OXOSPIRO[3.5]NON 7 YL) 4',9' DIHYDROSPIRO(CYCLOBUTANE 1,3' XANTHEN) 1'(2'H) ONE; 9' (7 HYDROXY 9 OXOSPIRO[4.5]DEC 8 YL) 4',9' DIHYDROSPIRO(CYCLOBUTANE 1,3' XANTHEN) 1'(2'H) ONE; CYCLOHEXANONE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG IDENTIFICATION; DRUG POTENCY; HUMAN; HUMAN CELL; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RACEMIZATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMAL FEED; ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CYCLOHEXANONES; HUMANS; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHENES;

EID: 49449105301     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8003587     Document Type: Article

References (37)

1. Tatemoto, K.; Carlquist, M.; Mutt, V. Neuropeptide Y. A Novel Brain Peptide with Structural Similarities to Peptide YY and Pancreatic Polypeptide. Nature 1982, 296, 659-660.
2. Clark, J. T.; Kalra, P. S.; Crowley, W. R.; Kalra, S. P. Neuropeptide Y and Human Pancreatic Polypeptide Stimulate Feeding Behavior in Rats. Endocrinology 1984, 115, 427-429.
3. Stanley, B. G.; Leibowitz, S. F. Neuropeptide Y: Stimulation of Feeding and Drinking by Injection into the Paraventricular Nucleus. Life Sci. 1984, 35, 2635-2642.
4. Tatemoto, K.; Mutt, V. Isolation of Two Novel Candidate Hormones Using a Chemical Method for Finding Naturally Occurring Polypeptides. Nature 1984, 285, 417-418.
5. Stanley, B. G.; Kyrkoulim, S. E.; Lampert, S.; Leibowitz, S. F. Neuropeptide Y Chronically Injected into the Hypothalamus: A Powerful Neurochemical Inducer of Hyperphagia and Obesity. Peptides 1986, 7, 1189-1192.
6. Zarjevski, N.; Cusin, I.; Vettor, R.; Rohner-Jeanrenaud, F.; Jeanrenaud, B. Chronic Intracerebroventricular Neuropeptide-Y Administration to Normal Rats Mimics Hormonal and Metabolic Changes of Obesity. Endocrinology 1993, 133, 1753-1758.
7. Kalra, S. P.; Dube, M. G.; Sahu, A.; Phelps, C. P.; Kalra, P. S. Neuropeptide Y Secretion Increases in the Paraventricular Nucleus in Association with Increased Appetite for Food. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 10931-10935.
8. White, J. D.; Olchovsky, D.; Kershaw, M.; Berelowitz, M. Increased Hypothalamic Contents of Preproneuropeptide-Y Messenger Ribonucleic Acid in Streptozotocin-Diabetic Rats. Endocrinology 1990, 126, 765-772.
9. Sanacora, G.; Kershaw, M.; Finkelstein, J. A.; White, J. D. Increased Hypothalamic Content of Preproneuropeptide Y Messenger Ribonucleic Acid in Genetically Obese Zucker Rats and Its Regulation by Food Deprivation. Endocrinology 1990, 127, 730-737.
10. Kesterson, R. A.; Huszar, D.; Lynch, A. A.; Simerly, R. B.; Cone, R. D. Induction of Neuropeptide Y Gene Expression in the Dorsal Medial Hypothalamic Nucleus in Two Models of the Agouti Obesity Syndrome. Mol. Endocrinol. 1997, 11, 630-637.
11. Guan, X.-M.; Yu, H.; Van der Ploeg, L. H. T. Evidence of Altered Hypothalamic Pro-opiomelanocortin/neuropeptide Y mRNA Expression in Tubby Mice. Mol. Brain Res. 1998, 59, 273-279.
12. Erikson, J. C.; Hollopeter, G.; Palmiter, R. D. Attenuation of the Obesity Syndrome of ob/ob Mice by the Loss of Neuropeptide Y. Science 1996, 274, 1704-1707.
13. Blomqvist, A. G.; Herzog, H. Y-Receptor Subtypes. How Many More? Trends. Neurosci. 1997, 20, 294-298.
14. Gerald, C.; Walker, M. W.; Criscione, L.; Gustafson, E. L.; Batzl-Hartmann, C.; Smith, K. E.; Vaysse, P.; Durkin, M. M.; Laz, T. M.; Linemeyer, D. L.; Schaffhauser, A. O.; Whitebread, S.; Hofbauer, K. G.; Taber, R. I.; Branchek, T. A.; Weinshank, R. L. A Receptor Subtype Involved in Neuropeptide-Y-Induced Food Intake. Nature 1996, 382, 168-171.
15. Marsh, D. J.; Hollopeter, G.; Kafer, K. E.; Palmiter, R. D. Role of the Y5 Neuropeptide Y Receptor in Feeding and Obesity. Nat. Med. 1998, 4, 718-721.
16. Pedrazzini, T.; Seydoux, J.; Kunstner, P.; Aubert, J. F.; Grouzmann, E.; Beermann, F.; Brunner, H. R. Cardiovascular Response, Feeding Behavior and Locomotor Activity in Mice Lacking the NPY Y1 Receptor. Nat. Med. 1998, 4, 722-726.
17. Kanatani, A.; Mashiko, S.; Murai, N.; Sugimoto, N.; Ito, J.; Fukuroda, T.; Fukami, T.; Morin, N.; MacNeil, D. J.; Van der Ploeg, L. H. T.; Saga, Y.; Nishimura, S.; Ihara, M. Role of Y1 Receptor in the Regulation of Neuropeptide Y-Mediated Feeding Regulation: Comparison of Wild-Type, Y1 Receptor-Deficient, and Y5 Receptor-Deficient Mice. Endocrinology 2000, 141, 1011-1016.
18. 5 aAntagonists. Bioorg. Med. Chem. Lett. 2004, 14, 597-599.
19. 5 Receptor Antagonists for the Treatment of Obesity. Bioorg. Med. Chem. 2004, 12, 4717-4723.
20. Rueeger, H.; Gerspacher, M.; Buehlmayer, P.; Rigollier, P.; Yamaguchi, Y.; Schmidlin, T.; Whitebread, S.; Nuesslein-Hildesheim, B.; Nick, H.; Cricione, L. Discovery and SAR of Potent, Orally Available and Brain-Penetrable 5,6-Dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen Derivatives as Neuropeptide Y Y5 Receptor Antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 2451-2457.
21. Aquino, C. J.; Ramanjulu, J. M.; Heyer, D.; Daniels, A. J.; Palazzo, F.; Dezube, M. Synthesis and Structure Activity Relationship of Guanidines as NPY Y5 Antagonists. Bioorg. Med. Chem. 2004, 12, 2691-2708.
22. Hammond, M.; Elliott, R. L.; Gillaspy, M. L.; Hager, D. C.; Hank, R. F.; LaFlamme, J. A.; Oliver, R. M.; DaSilva-Jardine, P. A.; Stevenson, R. W.; Mack, C. M.; Cassella, J. V. Structure-Activity Relationships in a Series of NPY Y5 Antagonists: 3-Amido-9-ethylcarbazoles, Core-Modified Analogues and Amide Isosteres. Bioorg. Med. Chem. Lett. 2003, 13, 1989-1992.
23. (a) Islam, I.; Dhanoa, D.; Finn, J.; Du, P.; Walker, M. W.; Salon, J. A.; Zhang, J.; Gluchowski, C. Discovery of Potent and Selective Small Molecule NPY Y5 Receptor Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 1767-1769.
24. (b) Finn, J.; Pelham, D.; Walker, M. W.; Gluchowski, C. High-Throughput Synthesis Optimization of Sulfonamide NPY Y5 Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 1771-1774.
25. Tabuchi, S.; Itani, H.; Sakata, Y.; Oohashi, H.; Satoh, Y. Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptor. Part 1: 2-Oxobenzothiazolin-3- acetic Acid Derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 1171-1175.
26. Satoh, Y.; Hatori, C.; Ito, H. Novel Potent Antagonists of Human Neuropeptide Y-Y5 Receptor. Part 4: Tetrahydrodiazabenzazulene Derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 1009-1011.
27. (a) Itani, H.; Ito, H.; Sakata, Y.; Hatakeyama, Y.; Oohashi, H.; Satoh, Y. Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptors. Part 2: Substituted Benzo[a]cycloheptene Derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 757-761.
28. (b) Itani, H.; Ito, H.; Sakata, Y.; Hatakeyama, Y.; Oohashi, H.; Satoh, Y. Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptors. Part 3: 7-Methoxy-1-hydroxy-1-substituted Tetraline Derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 799-802.
29. Sato, N.; Takahashi, T.; Shibata, T.; Haga, Y.; Sakuraba, A.; Hirose, M.; Sato, M.; Nonoshita, K.; Koike, Y.; Kitazawa, H.; Fujino, N.; Ishii, Y.; Ishihara, A.; Kanatani, A.; Fukami, T. Design and Synthesis of the Potent, Orally Available, Brain-Penetrable Arylpyrazole Class of Neuropeptide Y5 Receptor Antagonists. J. Med. Chem. 2003, 46, 666-669.
30. Kanatani, A.; Ishihara, A.; Iwaasa, H.; Nakamura, K.; Okamoto, O.; Hidaka, M.; Ito, J.; Fukuroda, T.; MacNeil, D. J.; Van der Ploeg, L. H. T.; Ishii, Y.; Okabe, T.; Fukami, T.; Ihara, M. L-152,804: Orally Active and Selective Neuropeptide Y Y5 Receptor Antagonist. Biochem. Biophys. Res. Commun. 2000, 272, 169-173.
31. 34 NPY action in rodents: Mashiko, S.; Ishihara, A.; Iwaasa, H.; Sano, H.; Oda, Z.; Ito, J.; Yumoto, M.; Okawa, M.; Suzuki, J.; Fukuroda, T.; Jitsuoka, M.; Morin, N. R.; MacNeil, D. J.; Van der Ploeg, L. H. T.; Ihara, M.; Fukami, T.; Kanatani, A. Characterization of Neuropeptide Y (NPY) Y5 Receptor-Mediated Obesity in Mice: Chronic Intracerebroventricular Infusion of D-Trp(34)NPY. Endocrinology 2003, 144, 1793-1801.
32. Ishihara, A.; Kanatani, A.; Mashiko, S.; Tanaka, T.; Hidaka, M.; Gomori, A.; Iwaasa, H.; Murai, N.; Egashira, S.; Murai, T.; Mitobe, Y.; Matsushita, H.; Okamoto, O.; Sato, N.; Jitsuoka, M.; Fukuroda, T.; Ohe, T.; Guan, X.; MacNeil, D. J.; Van der Ploeg, L. H. T.; Nishikibe, M.; Ishii, Y.; Ihara, M.; Fukami, T. A Neuropeptide Y Y5 Antagonist Selectively Ameliorates Body Weight Gain and Associated Parameters in Diet-Induced Obese Mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 7154-7158.
33. Horning, E. C.; Horning, M. G. Methone Derivatives of Aldehydes. J. Org. Chem. 1946, 11, 95-99.
34. Jurd, L. Anthocyanidins and Related Compounds. IX. The Synthesis of 9-Phenacyl-5-oxototetrahydroxanthenes. J. Org. Chem. 1966, 31, 1639-1941.
35. For the experimental conditions for determination of plasma protein binding and P-gp efflucx index, see the following: Ohe, T.; Sato, M.; Tanaka, S.; Fujino, N.; Hata, M.; Shibata, Y.; Kanatani, A.; Fukami, T.; Yamazaki, M.; Chiba, M.; Ishii, Y. Effect of P-Glycoprotein-Mediated Efflux on Cerebrospinal Fluid/Plasma Concentration Ratio. Drug Metab. Dispos. 2003, 31, 1251-1254.
36. For the preparation of 5,5-diethyl-1,3-hexanedione, see the following: Kon, G. A. R.; Linstead, R. P. The Chemistry of the 3-Carbon System. Prat IV. A Case of Retarded Mobility. J. Chem. Soc. 1925, 127, 815-821.
37. For the preparation of spiro[3.5]nonane-6,8-dione, see the following: Paulsen, H.; Antons, S.; Brandes, A.; Logers, M.; Muller, S. N.; Naab, P.; Schmeck, C.; Schneider, S.; Stoltefuss, J. Stereoselective Mukaiyama-Michael/ Michael/Aldol Domino Cyclization as the Key Step in the Synthesis of Pentasubstituted Arenes: An Efficient Access to Highly Active Inhibitors of Cholesteryl Ester Transfer Protein (CETP). Angew. Chem., Int. Ed. 1999, 38, 3373-3375.